Vesigenurtacel-L (HS-410) in the management of high-grade nonmuscle invasive bladder cancer

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

Unlike other malignancies, the death rate of bladder cancer has not declined in several decades, highlighting the need for new treatment options. In the emerging era of immunotherapy, therapeutic cancer vaccines are an attractive option to cure, control and prevent cancer. Despite this, finding a feasible and efficacious vaccine platform has proven elusive across all malignancies. Vesigenurtacel-L is the first whole cell, allogeneic vaccine intended to treat high-grade, nonmuscle invasive bladder cancer. This type of vaccine technology for bladder cancer is novel, and has the potential to be both economically and logistically feasible.

Original languageEnglish (US)
Pages (from-to)2673-2682
Number of pages10
JournalFuture Oncology
Volume12
Issue number23
DOIs
StatePublished - Dec 1 2016

Keywords

  • allogeneic
  • bladder cancer
  • immunotherapy
  • nonmuscle invasive
  • therapeutic vaccine

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Vesigenurtacel-L (HS-410) in the management of high-grade nonmuscle invasive bladder cancer'. Together they form a unique fingerprint.

Cite this